Jan 18, 2023
CORMEDIX INC. ANNOUNCES PROMOTIONS IN COMMERCIAL AND TECH OPS
Dec 6, 2022
CORMEDIX INC. ANNOUNCES PRESENTATION AT CONFERENCE SHOWING MORTALITY RISK AND COMPLICATIONS IN PATIENTS EXPERIENCING CATHETER RELATED BLOOD STREAM INFECTIONS
Nov 10, 2022
CORMEDIX INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Nov 7, 2022
CORMEDIX INC. ANNOUNCES CMS REVISION TO NTAP REIMBURSEMENT OF DEFENCATH
Nov 2, 2022
CORMEDIX INC. TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 10
Oct 20, 2022
CORMEDIX INC. ANNOUNCES Abstract presentation at upcoming American Society of nephrology Conference
Sep 7, 2022
CorMedix Inc. to present at the H.C. Wainwright Annual Global investment conference
Aug 11, 2022
CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update
Aug 8, 2022
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES
Aug 1, 2022
CORMEDIX INC. TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 11
Jun 8, 2022
CorMedix to Participate at the JMP Securities Life Sciences Conference
May 12, 2022
CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES
May 3, 2022
CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12
Apr 7, 2022
CORMEDIX INC. ANNOUNCES SCIENTIFIC ADVISORY BOARD TO SUPPORT COMMERCIALIZATION and pipeline development
Apr 4, 2022
CORMEDIX INC. to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 29, 2022
CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Mar 28, 2022
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH
Mar 22, 2022
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
Mar 17, 2022
CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER
